Dupont Capital Management Corp Has $464,000 Position in InMode Ltd. (NASDAQ:INMD)

Dupont Capital Management Corp reduced its position in shares of InMode Ltd. (NASDAQ:INMD – Get Rating ) by 28.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,942 shares of the healthcare company’s stock after selling 6,245 shares during the period. Dupont Capital Management Corp’s holdings in InMode were worth $464,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Whittier Trust Co . of Nevada Inc. raised its stake in InMode by 7.4% during the second quarter. Whittier Trust Co . of Nevada Inc. now owns 29,939 shares of the health care company’s stock valued at $670,000 after acquiring an additional 2,072 shares during the period. Point72 Asset Management LP bought a new position in shares of InMode in the second quarter valued at $5,479,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of InMode by 614.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,947 shares of the health care company’s stock worth $828,000 after buying an additional 31,773 shares during the last quarter. Advisory Services Network LLC raised its stake in shares of InMode by 7.1% in the first quarter. Advisory Services Network LLC now owns 89,064 shares of the health care company’s stock valued at $3,287,000 after purchasing an additional 5,920 shares during the last quarter. Finally, Baltimore Washington Financial Advisors Inc. raised its stake in shares of InMode by 99.2% in the second quarter. Baltimore Washington Financial Advisors Inc. now owns 288,344 shares of the health care company’s stock valued at $6,461,000 after purchasing an additional 143,576 shares during the last quarter. Institutional investors own 55.24% of the company’s shares.

Wall Street analysts predict growth

INMD has been the subject of several recent analyst reports. TheStreet cut InMode from a “b-” rating to a “c+” rating in a research note on Tuesday, September 20th. Jefferies Financial Group initiated coverage on InMode in a research note on Wednesday, October 12th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Barclays initiated coverage on InMode in a research note on Wednesday, December 21st. They issued an “overweight” rating and a $44.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, according to MarketBeat, the stock has an average rating of “Buy” and an average target price of $46.17.

InMode shares fall 0.6%

Shares of INMD stock opened at $32.70 on Friday. The firm has a market capitalization of $2.72 billion, a P/E ratio of 15.80 and a beta of 2.19. InMode Ltd. it has a twelve month low of $20.60 and a twelve month high of $54.68. The stock’s fifty-day simple moving average is $35.83, and its 200-day simple moving average is $32.86.

InMode (NASDAQ:INMD – Get Rating ) last issued its quarterly earnings data on Thursday, October 27th. The healthcare company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.05). The firm had revenue of $121.23 million for the quarter, compared to the consensus estimate of $120.70 million. InMode had a return on equity of 39.52% and a net margin of 40.93%. As a group, equities research analysts expect that InMode Ltd. will post 2.09 EPS for the current fiscal year.

InMode Company Profile (Get Rating)

InMode Ltd. designs, develops, manufactures and markets minimally invasive aesthetic medical products based on its radiofrequency-assisted lipolysis and deep subcutaneous fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and facial contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures.

Featured stories

Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for InMode Ltd. ( NASDAQ:INMD – Get Rating ).

This instant news alert was created from scientific narrative technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider InMode, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s highest-rated and best-rated research analysts and the stocks they recommend to their clients every day. MarketBeat has identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches up… and InMode wasn’t on the list.

While InMode currently has a “Buy” rating among analysts, top analysts believe these five stocks are better buys.

View Five Shares Here